BioSpace News Archive

ASC Therapeutics will provide a comprehensive review of IND-enabling studies of ASC618, a second-generation gene therapy for hemophilia A, at the 25th Annual Meeting of The American Society of Gene and Cell Therapy held May 16-19, 2022 in Washington, D.C. These studies were included in a filing to the U.S. Food and Drug Administration leading to IND clearance of ASC618.

CANbridge Pharmaceuticals Inc. announced the presentation of the initial data from its gene therapy research agreement with the Horae Gene Therapy Center, at the UMass Chan Medical School, at the ASGCT 25th Annual Meeting, in Washington DC.

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022.

The corporate intelligence reports predict that the global interventional radiology market will record an excellent compound annual growth rate of 6.7 % over the forecast years i.e. 2016 to 2021.

QIAGEN N.V. announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.

Inventiva announced the signing of a €50 million bullet credit facility agreement with the European Investment Bank.

Pharnext SA announces new results from the ongoing open-label follow-up extension study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT-FU trial, which followed the first double-blind, placebo controlled Phase III study, the PLEO-CMT trial.

Royal Philips, a global leader in health technology, announced at EuroPCR the international launch of EchoNavigator 4.0 [1], the new release of its advanced image-guided therapy solution for the treatment of structural heart disease.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced that it plans to release its unaudited financial results for the first quarter of 2022 before the U.S. market opens on May 31, 2022.

Royal Philips, a global leader in health technology, is showcasing innovations at EuroPCR that can enable interventionists to perform ultra-low contrast percutaneous coronary intervention procedures with greater confidence and clarity.